Literature DB >> 30230964

Active Surveillance as First-Line Management of Papillary Microcarcinoma.

Yasuhiro Ito1, Akira Miyauchi1.   

Abstract

Papillary thyroid microcarcinoma (PMC) is defined as papillary thyroid carcinoma ≤10 mm. Active surveillance of PMC without high-risk features, such as clinical node metastasis, distant metastasis, and clinical evidence of significant extrathyroid extension, was initiated in two Japanese hospitals in the mid-1990s. This strategy was incorporated into guidelines in Japan in 2010 and in the United States in 2015. In studies conducted by the two hospitals, most PMCs grew very slowly or did not grow, and none of the patients during active surveillance showed distant metastasis or died of thyroid carcinoma. Furthermore, none of the patients who underwent surgery after progression signs were detected showed significant recurrence. Therefore, we conclude that active surveillance should be the first line in management of low-risk PMC, because it is safer and less costly than immediate surgery. Active surveillance helps in avoiding adverse events of surgery and is an economical strategy.

Entities:  

Keywords:  active surveillance; guidelines; immediate surgery; medical cost; papillary thyroid microcarcinoma; unfavorable events

Year:  2018        PMID: 30230964     DOI: 10.1146/annurev-med-051517-125510

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  12 in total

1.  Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up.

Authors:  R Michael Tuttle; Ali S Alzahrani
Journal:  J Clin Endocrinol Metab       Date:  2019-03-15       Impact factor: 5.958

2.  Nonsurgical Thermal Ablation of Thyroid Nodules: Not if, but Why, When, and How?

Authors:  Laszlo Hegedüs; Akira Miyauchi; R Michael Tuttle
Journal:  Thyroid       Date:  2020-09-07       Impact factor: 6.568

Review 3.  Updates on the Management of Thyroid Cancer.

Authors:  Katherine A Araque; Sriram Gubbi; Joanna Klubo-Gwiezdzinska
Journal:  Horm Metab Res       Date:  2020-02-10       Impact factor: 2.936

4.  What is the difference between the tall cell variant and the classic type of papillary thyroid carcinoma on ultrasonography?

Authors:  Haejung Kim; Young Lyun Oh; Jae Hoon Chung; Soo Yeon Hahn; Ko Woon Park; Tae Hyuk Kim; Jung Hee Shin
Journal:  Ultrasonography       Date:  2022-02-21

5.  Comparison between 2015 ATA guidelines and Italian Consensus for DTC management. A commented report.

Authors:  Giulia Arrigoni; Erika Crosetti; Milena Freddi; Alessandro Piovesan; Ruth Rossetto Giaccherino; Giovanni Succo; Nicola Palestini
Journal:  Acta Otorhinolaryngol Ital       Date:  2022-02       Impact factor: 2.124

Review 6.  The Efficacy and The Safety of Ultrasound-guided Ablation Therapy for Treating Papillary Thyroid Microcarcinoma.

Authors:  Jifan Chen; Jing Cao; Fuqiang Qiu; Pintong Huang
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

Review 7.  Active surveillance for patients with very low-risk thyroid cancer.

Authors:  Shivangi Lohia; Martin Hanson; R Michael Tuttle; Luc G T Morris
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-02-07

8.  Expression of Class III Beta-Tubulin Is Associated with Invasive Potential and Poor Prognosis in Thyroid Carcinoma.

Authors:  Hee Young Na; Mira Park; Young A Kim; Jae Kyung Won; Young Joo Park; Sun Ah Shin; Sejoon Lee; Sohee Oh; Ji Eun Kim
Journal:  J Clin Med       Date:  2020-11-26       Impact factor: 4.241

9.  Bibliometric insights in advances of papillary thyroid microcarcinoma: Research situation, hot points, and global trends.

Authors:  Kefan Chen; Zhongqing Wang; Wei Sun; Dalin Zhang; Ting Zhang; Liang He; Hao Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-08       Impact factor: 6.055

10.  Expression Profiles of Circular RNAs in Human Papillary Thyroid Carcinoma Based on RNA Deep Sequencing.

Authors:  Chengzhou Lv; Wei Sun; Jiapeng Huang; Yuan Qin; Xiaoyu Ji; Hao Zhang
Journal:  Onco Targets Ther       Date:  2021-06-21       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.